Healthcare Sales & Marketing Network News: NXY-059

Searching News Database: NXY-059

HSMN NewsFeed - 28 Jun 2007
Renovis Announces Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Oct 2006
NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 May 2006
Renovis Names Donald R. Joseph as Senior Vice President, Corporate Development and General Counsel
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Mar 2006
Headline Results From CHANT Safety and Tolerability Study In Intracerebral Hemorrhage (ICH) Show NXY-059 Achieved Key Endpoints
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Mar 2006
Renovis Announces That Headline Results From CHANT Safety and Tolerability Trial in Intracerebral Hemorrhage (ICH) Show NXY-059 Achieved Key Endpoints
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Feb 2006
New England Journal of Medicine Publishes NXY-059 Study, the First International Study of a Neuroprotectant to Show Reduced Disability Following Acute Ischemic Stroke
Biopharmaceuticals Neurology

Return to NewsFeed

Additional items found! 13

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 13 additional stories matching:
NXY-059
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.